Mithra Signs License and Supply Agreement for Commercialization of Tibelia® in Italy

  • Mithra grant a license to Farmitalia for commercialization of its hormone treatment Tibelia® in Italy
  • Tibelia® is currently marketed in 13 countries through existing license and supply agreements
Liege, Belgium, 07 January 2020 – 7 :30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has entered into a license and supply agreement with Farmitalia for the commercialization of Tibelia® in Italy.

Mithra Receives EUR 2.9 Million in Non-dilutive Funding

Liege, Belgium, 23 December 2019 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has been granted EUR 2.9 million in non-dilutive funding from the Walloon Region. The grant follows a decision by Mr Willy Borsus, Vice President of the Walloon Government and Minister of Economy, Foreign Trade, Research & Innovation, New Technologies, Agriculture and Urban and Spatial Planning.

Mithra and Searchlight sign LSA for Myring™ in Canada

  • Mithra grants exclusive license for vaginal contraceptive ring to Searchlight Pharma for commercialization in Canada
  • With Mithra’s two leading products Myring™ and Estelle®, Searchlight Pharma aims to further expand its growing footprint in Women’s Health

Liege, Belgium, 16 December 2019 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has entered into an exclusive license and supply agreement with Searchlight Pharma (Searchlight) for the commercialization of its hormonal contraceptive ring Myring™ in Canada.

Mithra Signs LSA for Commercialization of Myring™ in Switzerland

  • Mithra grants license to Labatec for commercialization of vaginal contraceptive ring in Switzerland
  • Production of Myring™ at the Mithra CDMO facility in Belgium
  • Agreement follows licensing deals with major international market leaders for commercialization of Myring™
Liege, Belgium, 05 December 2019 – 7 :30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has entered into a license and supply agreement with Labatec for the commercialization of its hormonal contraceptive ring Myring™ in Switzerland.

European Authorities Approve Advantageous Modifications to Myring™ labelling

  • Removal of requirement for special temperature storage for vaginal contraceptive ring Myring™
  • Competitive advantage in terms of reduced costs and convenience for distributors, pharmacists and patients
  • Similar labelling to be pursued in the United States
Liege, Belgium, 08 November 2019 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that the European Authorities has approved two noteworthy modifications relating to the change in the shelf-life and storage conditions of its vaginal contraceptive ring Myring.

Mithra Signs LSA for Commercialization of Myring™ and Tibelia® in Eastern Europe

  • Mithra grants exclusive license to Aicore Life Sciences for commercialization of Myring™ and Tibelia® in Eastern Europe
  • Production of Myring™ at the Mithra CDMO facility in Belgium
  • Agreement follows licensing deals with major international market leaders for commercialization of Myring™
Liege, Belgium, 24 October 2019 – 7:30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has entered into two exclusive license and supply agreements with Aicore Life Sciences for the registration and commercialization of two major products in contraception and menopause in Eastern Europe: the hormonal contraceptive ring Myring™ and the tibolone-based product Tibelia® for use in Hormone Therapy (HT).

Mithra Signs Agreement for Commercialization of Myring™ in China with Abbott

  • Mithra grants an exclusive license for commercialization of vaginal contraceptive ring in China
  • The introduction of a long acting contraceptive method represents a compelling new alternative for women in China

Liege, Belgium, 14 October 2019, 7:30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has entered into an exclusive license and commercialization agreement with Abbott for the registration and launch of its hormonal contraceptive ring Myring™ in China.

Mithra Signs LSA for Commercialization of Estelle® and Myring™ in Israel

  • Mithra grants exclusive license to Dexcel Pharma for commercialization of its two leading contraceptive products in Israel
  • Dexcel Pharma is Israel’s largest private pharmaceutical company
  • Production at the Mithra CDMO facility in Belgium
Liege, Belgium, 20 August 2019 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has entered into two exclusive license and supply agreements with Dexcel Pharma for the commercialization in Israel of two major products in contraception:  the combined oral pill Estelle® and the hormonal ring Myring™.

Mithra CDMO Strengthens its Management Team and Accelerates Key R&D Programs

  • Strengthening of management team with key appointments of Chief Scientific Officer and Plant Manager, to support the strategy execution of Mithra CDMO
  • Consolidation of R&D and manufacturing teams with 30% increase in highly qualified staff since the beginning of the year
  • Donesta® and PeriNesta® Phase III studies ready to begin, pending approval by authorities
  • Launch of production of Estelle® clinical validation batches for both U.S. and EU filing
  • Positive outcome of the registration procedure for Myring™, adding 15 new Market Authorizations in Europe
Liege, Belgium, 16 July 2019 – 7 :30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, announces it has strengthened its CDMO Management team with the appointments of Dr Graham Dixon as Chief Scientific Officer and Mr Renaat Baes as Plant Manager.

Mithra Signs LSA for Commercialization of Myring™ in Germany, the biggest market in Europe

  • Mithra grants exclusive license to Hormosan for commercialization of vaginal contraceptive ring in Germany
  • Germany is the largest European market in terms of volumes, with 3 million vaginal rings sold per year
  • Agreement follows licensing deals for Myring™ with market leaders in the U.S., Europe, Russia, Australia, Middle East, Latin and South America

Liege, Belgium, 28 May 2019 – 7 :30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has entered into an exclusive license and supply agreement with Hormosan for the commercialization of its hormonal contraceptive ring Myring™, bioequivalent to Nuvaring®, in Germany. Hormosan is a subsidiary of the innovation-driven pharmaceutical company Lupin Group, offering low-cost generics in Germany that offer added value relevant to therapy.